Primary endpoint met; median time to onset of symptom relief achieved in 1.28 hours , significantly faster versus placebo ...

Investing.com -- Pharvaris N.V. (NASDAQ:PHVS) stock jumped 20% after the company announced positive topline results from its pivotal Phase 3 RAPIDe-3 study for deucrictibant, an oral treatment for ...

General Atlantic is building its position just as Pharvaris nears pivotal readouts. This article breaks down what the fund ...

This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question ...

Termination of the waiting period under the HSR Act satisfied one of the conditions for consummation of the Merger. BioCryst expects the Merger to close in the first quarter of 2026, subject to other ...

In this video, Rebecca Saff, MD, PhD, allergy/immunology fellowship director and assistant physician at Massachusetts General ...

If facial and hand swelling, laryngeal swelling, and abdominal pain of unknown cause persist for two to three days without any special reason or are repeated periodically, it is necessary to consider ...

Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...

Among pediatric patients with hereditary angioedema, on-demand sebetralstat was generally safe and used within a median time of 30 minutes after attack onset, according to interim phase 3 trial ...

In late November 2025, Ionis Pharmaceuticals announced a positive opinion from the European Medicines Agency’s Committee for Donidalorsen, a hereditary angioedema therapy, with a final decision ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

In March 2025, the FDA approved OMLYCLO in 75 mg/0.5 mL and 150 mg/mL solutions in a single-dose prefilled syringe for subcutaneous injection for the treatment of moderate to severe persistent asthma, ...